MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease.
The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).
| Mikhil N Bamne, PhD | |
| (412) 648-6920 | |
| [email protected] |
| Jude Jonassaint, RN | |
| 412-692-2086 | |
| [email protected] |
> 18 Years
Not Applicable
Interventional
All
Dietary Supplement
Subjects
African American
Patients with sickle cell anemia
18 years old or older
Control
African American healthy controls
18 years of age or older
Pregnancy,
Known hypertension,
Hemodialysis and active obstructive sleep apnea requiring treatment.
Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.